Lutonix 018 Drug-Coated PTA Catheter

BD (Becton, Dickinson and Company)

(800) 562-0027


• Compatible with up to a 0.018-inch guidewire

• Low sheath profile (4–5 F)

• Low crossing profile

• Proven safety and efficacy

• Full superficial femoral artery size matrix (4–6 X 40–220 mm and 7 X 40–60 mm)

BD (Becton, Dickinson and Company) has announced the introduction of the Lutonix 018 drug-coated percutaneous transluminal angioplasty (PTA) catheter, the first drug-coated balloon (DCB) approved for use with a 0.018-inch guidewire. Based on the company’s Ultraverse 018 PTA dilatation catheter and utilizing the same drug coating as the Lutonix 035 DCB, the Lutonix 018 DCB has a low sheath profile (4–5 F) and a crossing profile 20% lower than the lowest profile 0.035-inch DCB. The Lutonix 018 DCB is available in diameters of 4 to 7 mm and lengths of 40 to 220 mm.*

“By virtue of its lower profile and compatibility with smaller guidewires, the Lutonix 018 DCB will allow physicians to treat more complex lesions from more access sites without the need to exchange to a 0.035-inch guidewire. Combined with the 220-mm lengths, this represents a significant improvement in our ability to efficiently and effectively deliver a proven drug technology,” commented Constantino S. Peña, MD, an interventional radiologist at Miami Vascular Specialists in Miami, Florida.

The Lutonix 018 DCB is now available for sale in the United States and is pending CE Mark approval.

*For the 7-mm platform, only the 40- and 60-mm lengths are available as of January 2019.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.